A major strength of our study is the inclusion of broad tumor molecular profiling, covering BRCA1/2, TP53, and other HR pathway genes, integrated with GI analysis for HRD assessment The cross platform genomic instability results comparison conducted contributes to ongoing international efforts aiming to harmonize HRD assays. This evidence concerns the gene BRCA1 and neoplasm.